Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

Journal of Infectious Diseases

Volumn 185, Issue 10, 2002, Pages 1506-1510

  Izopet, Jacques ^a   Souyris, Corinne ^a   Hance, Allan ^c   Sandres Sauné, Karine ^a   Alvarez, Muriel ^b   Pasquier, Christophe ^a   Clavel, François ^b   Puel, Jacqueline ^a   Massip, Patrice ^b  

^a Laboratoire de Virologie   (France)

^b CHU PURPAN   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; REFUSAL TO TREAT; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0037094101     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340215     Document Type: Article

References (16)

1. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
2. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
3. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
4. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
5. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
6. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor sensitive genotype
7. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
8. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
9. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
10. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
11. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
12. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
13. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients
14. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
15. +cell counts despite persistently detectable HIV load
16. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy